Texas Medicare Supplement Accredited Advisor
Danielle Kunkle of Benbrook, TX has recently completed the requirements of the national Medicare Supplement Accredited Advisor designation. As such, she was awarded the professional designation of "MSAA" and accorded 2008 membership in the National Association of Medicare Supplement Advisors.
The MSAA designation is achieved by completing, and passing, two concentrated courses on Medicare and Medicare Supplemental educational information. High ethical standards regarding consumer information in these two important areas, is the objective of the designation and national association.
As a professional Medicare Supplement Accredited Advisor, Danielle Kunkle has demonstrated a willingness to achieve educational goals beyond the normal insurance industry standards.
This proficiency is necessary at a time when the Medicare program is, itself, undergoing great change. Consumers, more than ever, are going to require proper explanation and updates regarding existing and continuing changes in Medicare and Medicare Supplemental insurance.The MSAA designation illustrates the ability to achieve these goals for today's retirees.
Included in the designation curriculum are a proficiency and understanding of Medicare "DRG's" and how they affect the consumer, Medicare appeals processes, an understanding of Medicare's $1000 reward process, an explanation of consumer confusion regarding "Skilled Care" and its relationship to Long Term Care, and an understanding of the Home Health Care benefits of Medicare.
Changes in Medicare and Medicare Supplement offerings which started in 2006, and the addition of Medicare Part D (prescription drug) benefits, require a great deal of understanding for Medicare recipients. Meeting this need is the goal of the MSAA professional and the national NAMSA association.
Danielle Kunkle is part of Consumer Benefits Group, LLP, a family-owned independent insurance agency in Fort Worth, Texas, that specializes in Medicare supplements, Medicare Advantage plans and Part D drug plans.
|
